Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jonathan Fleming
AddedMar 31, 2024
UpdatedJun 28, 2026
Jonathan Fleming

Jonathan Fleming

Board of Directors, Quiver Bioscience

WebsiteCrunchbaseLinkedIn

Jonathan Fleming's Career

Quiver Bioscience
Quiver Bioscience

Cambridge, MA, US

Board of Directors
Onc.AI
Onc.AI

San Carlos, CA, US

Board Member· Board
Continuus Pharmaceuticals
Continuus Pharmaceuticals

Woburn, MA, US

Board Member· Board
EnClear Therapies
EnClear Therapies

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jonathan Fleming's Career

Quiver Bioscience
Quiver Bioscience
Pre-Seed$22.5M292013Cambridge, MA, US
Board of Directors

Recent news

Quiver Bioscience Receives Strategic Investment From the Porta Family to Advance UBE3A ASO Therapeutic Program for Dup15q SyndromeBioSpace · 2026
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic EpilepsiesBusiness Wire · 2026
Quiver Bioscience Secures Non-Dilutive Funding to Enhance CNS Genetic Medicine Drug Discovery Platform Capabilities and Advance Powerful AI/ML-Based In Vitro / In Silico Predictor of CNS Drug SafetyBusiness Wire · 2025

Leadership at Quiver Bioscience

Aayush ShroffAayush ShroffResearch Associate III
Adam CohenAdam CohenScientific Advisory Board Member
Aishwarya DhandapaniAishwarya DhandapaniAssociate Scientist
Alan KopinAlan KopinScientific Advisory Board Member
Amy ElderAmy ElderConsulting Director of Chemistry
Anne CarpenterAnne CarpenterScientific Advisory Board Member

Similar to Quiver Bioscience

Verge GenomicsVerge GenomicsSan Francisco, CA, USDrug Developmentest. 2015Verge GenomicsSan Francisco, CA, US · est. 2015

Verge Genomics accelerates drug development for neuro diseases using AI and human data.

Series B · $134.1M83
Quadrant BiosciencesQuadrant BiosciencesSyracuse, NY, USDiagnostics, Healthcareest. 2015Quadrant BiosciencesSyracuse, NY, US · est. 2015

Quadrant Biosciences develops and distributes innovative epigenetic diagnostics for early detection of neurological disorders.

Seed · $10M81
Curi BioCuri BioSeattle, WA, USBiotech, Drug Discoveryest. 2015Curi BioSeattle, WA, US · est. 2015

Curi Bio: Accelerating next-gen medicine discovery through human cells, systems, and data integration.

Series A · $20.4M45
System1 BiosciencesSystem1 BiosciencesSan Francisco, CA, USDrugs, Neurotherapeuticsest. 2017System1 BiosciencesSan Francisco, CA, US · est. 2017

System1 Biosciences, a neurotherapeutics firm, uses advanced tech to discover drugs for complex neurological disorders.

Series A · $25M30
Onc.AI
Onc.AI
Series A$31M302020San Carlos, CA, US
Board Member· Board

Leadership at Onc.AI

Julie HambletonJulie HambletonBoard Member
Juan-Pablo MasJuan-Pablo MasBoard Member
Salmaan AhmedSalmaan AhmedCo-Founder
Emir SandhuEmir SandhuBoard Member
Akshay NanduriAkshay NanduriCo-Founder
David Diaz-CasariegoDavid Diaz-CasariegoBoard Member

Similar to Onc.AI

Precision Health AIPrecision Health AINew York City, NY, USHealthcare, Oncologyest. 2016Precision Health AINew York City, NY, US · est. 2016

Precision Health AI: Leveraging AI for oncology, enhancing outcomes and value-based care.

Series A · $20M30
GenomOncologyGenomOncologyCleveland, OH, USHealthcare, Softwareest. 2012GenomOncologyCleveland, OH, US · est. 2012

GenomOncology: Transforming data into actionable insights for improved cancer care.

Pre-Seed · $2.9M62
OncoPrecisionOncoPrecisionNew York City, NY, USCancer Treatmentest. 2020OncoPrecisionNew York City, NY, US · est. 2020

Developing advanced tech for personalized cancer treatment and aiding in transformative therapy creation.

Seed · $4.2M37
OncoLensOncoLensAtlanta, GA, USTumor Board Softwareest. 2016OncoLensAtlanta, GA, US · est. 2016

OncoLens: Streamlining cancer case reporting with our efficient tumor board software solution.

Series A · $11.8M39
Continuus Pharmaceuticals
Continuus Pharmaceuticals
Series B$9.1M492012Woburn, MA, US
Board Member· Board

Leadership at Continuus Pharmaceuticals

Mark R. BamforthMark R. BamforthBoard Member
Bayan TakizawaBayan TakizawaCo-Founder
Salvatore MasciaSalvatore MasciaCo-Founder

Similar to Continuus Pharmaceuticals

Continuity PharmaContinuity PharmaWest Lafayette, IN, USManufacturing Systemsest. 2018Continuity PharmaWest Lafayette, IN, US · est. 2018

Continuity Pharma: Modern, efficient systems for manufacturing essential generic medicines.

Seed · $1.5M9
Selkirk PharmaSelkirk PharmaSpokane, WA, USPharmaceuticalsest. 2018Selkirk PharmaSpokane, WA, US · est. 2018

Selkirk Pharma: A leading Contract Manufacturing Organization for the pharmaceutical industry.

Series B · $82.1M64
Societal CdmoSocietal CdmoExton, PA, USPharmaceuticalsest. 1982Societal CdmoExton, PA, US · est. 1982

Societal CDMO, a leading bi-coastal medical organization, offers comprehensive pharmaceutical development, manufacturing, and logistics services globally.

Public275
Pharmaceutics InternationalPharmaceutics InternationalHunt Valley, MD, USDrug Developmentest. 2016Pharmaceutics InternationalHunt Valley, MD, US · est. 2016

Founded in 1994, Pharmaceutics International, Inc. is a contract development and manufacturing firm specializing in biological research.

Private Equity · $148M375
EnClear Therapies
EnClear Therapies
Series A$12M122018Cambridge, MA, US
Board Member· Board

Leadership at EnClear Therapies

Jason CammJason CammBoard Member
Kasper RoetKasper RoetBoard Member
Anthony DePasquaAnthony DePasquaCEO
Zafi AvnurZafi AvnurBoard Member
Kevin EgganKevin EgganCo-Founder
Hillel BachrachHillel BachrachBoard Member

Jonathan Fleming's Co-Investors

Stanley MarksStanley MarksCo-invested · Onc.AI SeedFrederic KerrestFrederic KerrestCo-invested · Onc.AI SeedT. Chen FongT. Chen FongCo-invested · Onc.AI SeedT. Chen FongT. Chen FongCo-invested · Onc.AI Seed

Jonathan Fleming's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Jonathan Fleming

Christopher HenneyChristopher HenneyBoard Member · Anthera PharmaceuticalsMichael PelliniMichael PelliniBoard Member · Foundation MedicineAlvaro GuillemAlvaro GuillemCo-Founder · Renibus TherapeuticsDavid DoveDavid DoveBoard Member · Intera Oncology